MF
Frias, Miguel
Affiliation entities
Research groups
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| People living with HIV display increased anti-apolipoprotein A1 auto-antibodies, inflammation, and kynurenine metabolites : a case–control study | Frontiers in cardiovascular medicine | 2024 | 114 | 39 | |||
| Ferritin : a biomarker requiring caution in clinical decision | Diagnostics | 2024 | 98 | 126 | |||
| Associations between high-density lipoprotein particle’s proteome, subfractions and autoantibodies against apolipoprotein A1 in HIV patients | 92nd EAS (European Atherosclerosis Society) Congress | 2024 | 6 | 0 | |||
| Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic | Journal of neurology, neurosurgery and psychiatry | 2023 | 265 | 139 | |||
| High antibody titers against apolipoprotein-A1 in NAFLD: a possible link between fatty liver disease and CVD? | 90th European Atherosclerosis Society (EAS) congress | 2022 | 156 | 0 | |||
| Sphingosine‐1‐phosphate as a key player of insulin secretion induced by high‐density lipoprotein treatment | Physiological reports | 2021 | 255 | 160 | |||
| Autoantibodies directed against apolipoprotein-A1 as a potential contributor to Non-Alcoholic Fatty Liver Disease | 89th Europen Society of Atherosclerosis (EAS) | 2021 | 141 | 0 | |||
| Antibodies against apolipoprotein a-1 as disruptors of cellular cholesterol homeostasis promoting foam cell formation | 88th EAS (European Atherosclerosis Society) Congress | 2020 | 62 | 0 | |||
| High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases | Metabolism, clinical and experimental | 2020 | 187 | 0 | |||
| Auto-antibodies against apolipoprotein a-1 block cancer cells proliferation and induce apoptosis | Oncotarget | 2020 | 171 | 121 | |||
| HDL protects against myocardial ischemia reperfusion injury via miR-34b and miR-337 expression which requires STAT3 | PLOS ONE | 2019 | 290 | 189 | |||
| Anti-ApoA-1 IgGs in Familial Hypercholesterolemia Display Paradoxical Associations with Lipid Profile and Promote Foam Cell Formation | Journal of clinical medicine | 2019 | 239 | 167 | |||
| P5343 - The presence of anti-apolipoprotein A1 autoantibodies is associated with a pro-atherogenic profile in HIV-infected patients | ESC Congress 2019 together with World Congress of Cardiology | 2019 | 118 | 0 | |||
| ELISA methods comparison for the detection of auto-antibodies against apolipoprotein A1 | Journal of Immunological Methods | 2019 | 388 | 1 | |||
| Humoral immunity against HDL particle: a new perspective in cardiovascular diseases? | Current Pharmaceutical Design | 2019 | 275 | 0 | |||
| Separation of blood microsamples by exploiting sedimentation at the microscale | Scientific Reports | 2018 | 499 | 216 | |||
| Sphingosine-1-phosphate reduces ischaemia-reperfusion injury by phosphorylating the gap junction protein Connexin43 | Cardiovascular research | 2016 | 695 | 6 | |||
| Diabetes Mellitus Is Associated With Reduced High-Density Lipoprotein Sphingosine-1-Phosphate Content and Impaired High-Density Lipoprotein Cardiac Cell Protection | Arteriosclerosis, Thrombosis, and Vascular Biology | 2016 | 618 | 1 | |||
| Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury | PloS one | 2015 | 674 | 254 | |||
| CD14 as a Mediator of the Mineralocorticoid Receptor-Dependent Anti-apolipoprotein A-1 IgG Chronotropic Effect on Cardiomyocytes | Endocrinology | 2015 | 668 | 1 | |||
| High density lipoproteins and ischemia reperfusion injury: the therapeutic potential of HDL to modulate cell survival pathways | Advances in experimental medicine and biology | 2014 | 550 | 0 | |||
| HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity | Atherosclerosis | 2013 | 550 | 0 | |||
| JAK-STAT signaling and myocardial glucose metabolism | JAK-STAT | 2013 | 495 | 1 | |||
| Role of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in myocardial ischemia/reperfusion injury | Journal of Molecular and Cellular Cardiology | 2013 | 651 | 0 | |||
| HDLs protect pancreatic β-cells against ER stress by restoring protein folding and trafficking | Diabetes | 2012 | 638 | 0 | |||
| The natural cardioprotective particle HDL modulates connexin43 gap junction channels | Cardiovascular research | 2012 | 676 | 4 | |||
| Lipid-Induced Modulation of Protective Signalling Pathways in Cardiovascular Disease: The Role of High Density Lipoproteins | Current signal transduction therapy | 2012 | 570 | 0 | |||
| Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection | Cardiovascular drugs and therapy | 2012 | 629 | 0 | |||
| High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway | JAK-STAT | 2012 | 615 | 348 | |||
| Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis | Cardiovascular research | 2010 | 593 | 0 | |||
| Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: role of sphingosine-1-phosphate | Cardiovascular research | 2009 | 560 | 0 | |||
| The Prostaglandin E2 – Stat3 connection in hypertrophic and antiapoptotic responses in ventricular cardiomyocytes | 2008 | 977 | 381 | ||||
| The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis | Cardiovascular research | 2008 | 650 | 0 |
